Hair Growth Treatment

Technoderma Medicines Inc. Successfully Completes Phase 2a Clinical Trial

February 7, 2024 /

Interesting news from Technoderma Medicines Inc. about their Phase 2a trial. TDM-105795: Positive Results Observed Compared to Baseline Technoderma Medicines Inc. has completed a Phase 2a clinical trial for TDM-105795, “A Randomized, Double-Blind, Vehicle Controlled, Parallel Group, Multi-Dose Study to Evaluate the Efficacy and Safety of TDM-105795 in Male Subjects with Androgenetic Alopecia.” TDM-105795 is…

Aesthetic Tech Forum 2024: Advancements in Hair Restoration

January 25, 2024 /

The Aesthetic Tech Forum 2024 is underway (January 25th and 26th) and features a session titled “Revitalizing Radiance: Advances in Hair Restoration“.  Panelists include: Wajdie Ahmad, Executive Chairman & COO of Amplifica Holdings Group, Inc.; Amplifica is a biopharmaceutical company with several treatments in the pipeline targeted towards androgenic alopecia (AMP-303, AMP-203, and AMP-601). Drew…

Kangstem Biotech

January 19, 2024 /

Another Korean company has emerged with an exciting and potentially world-first approach to developing new hair loss therapies using hair follicle organoids. Kangstem Biotech Kangstem Biotech was established in 2010 and has several stem cell therapies in the pipeline for atopic dermatitis, rheumatoid arthritis, and osteoarthritis. Recently, Kangstem Biotech announced an expansion into hair loss…

Epibiotech EPI-001 Hair Regrowth Cell Therapy Update

September 5, 2023 /

Epibiotech EPI-001 Approval by the Ministry of Food and Drug Safety Update (12/21/2023) As of December 21st, 2023, Epibiotech has been approved by the Ministry of Food and Drug Safety to start Phase 1/2a clinical trials for its EPI-001 autologous dermal papilla cell treatment to treat androgenetic alopecia. Safety will be measured in Phase 1…

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.